MYC and B-cell non-Hodgkin lymphoma: In summary, we have demonstrated the successful application of CRISPR/Cas9-based targeted in situ editing of the LTR of the integrated retroviral genome as well as the insertionally activated major oncogene c-myc in an avian B-cell lymphoma-derived tumor cell line.